Synonym
HAMNO; NSC 111847; NSC-111847; NSC111847;
IUPAC/Chemical Name
(1Z)-1-[(2-Hydroxyanilino)methylidene]naphthalen-2-one
InChi Key
NADCEWZYITXLKJ-KAMYIIQDSA-N
InChi Code
InChI=1S/C17H13NO2/c19-16-10-9-12-5-1-2-6-13(12)14(16)11-18-15-7-3-4-8-17(15)20/h1-11,18,20H/b14-11-
SMILES Code
O=C(C=CC1=C/2C=CC=C1)C2=C/NC3=CC=CC=C3O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
HAMNO is a novel protein interaction inhibitor of replication protein A (RPA).
In vitro activity:
These data suggest that HAMNO selectively increased γ-H2AX staining in S-phase, indicative of increased replicative stress.
Reference: Cancer Res. 2014 Sep 15;74(18):5165-72. https://pubmed.ncbi.nlm.nih.gov/25070753/
In vivo activity:
Ser33 of RPA32, an ATR substrate, is highly phosphorylated after two hours of treatment with 20 μM of etoposide, which was reduced with the addition of 2 μM HAMNO, and was nearly absent at higher concentrations, demonstrating an in vivo effect of HAMNO as an inhibitor of RPA32 phosphorylation by ATR in mice.
Reference: Cancer Res. 2014 Sep 15;74(18):5165-72. https://pubmed.ncbi.nlm.nih.gov/25070753/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMF |
30.0 |
113.94 |
| DMSO |
30.0 |
113.94 |
| DMSO:PBS (pH 7.2) (1:30) |
0.3 |
0.95 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
263.30
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Glanzer JG, Liu S, Wang L, Mosel A, Peng A, Oakley GG. RPA inhibition increases replication stress and suppresses tumor growth. Cancer Res. 2014 Sep 15;74(18):5165-72. doi: 10.1158/0008-5472.CAN-14-0306. Epub 2014 Jul 28. PMID: 25070753; PMCID: PMC4201622.
In vitro protocol:
1. Glanzer JG, Liu S, Wang L, Mosel A, Peng A, Oakley GG. RPA inhibition increases replication stress and suppresses tumor growth. Cancer Res. 2014 Sep 15;74(18):5165-72. doi: 10.1158/0008-5472.CAN-14-0306. Epub 2014 Jul 28. PMID: 25070753; PMCID: PMC4201622.
In vivo protocol:
1. Glanzer JG, Liu S, Wang L, Mosel A, Peng A, Oakley GG. RPA inhibition increases replication stress and suppresses tumor growth. Cancer Res. 2014 Sep 15;74(18):5165-72. doi: 10.1158/0008-5472.CAN-14-0306. Epub 2014 Jul 28. PMID: 25070753; PMCID: PMC4201622.
1: Jang SW, Kim JM. The RPA inhibitor HAMNO sensitizes Fanconi anemia pathway-
deficient cells. Cell Cycle. 2022 Jul;21(14):1468-1478. doi:
10.1080/15384101.2022.2074200. Epub 2022 May 11. PMID: 35506981; PMCID:
PMC9278452.
2: Dueva R, Krieger LM, Li F, Luo D, Xiao H, Stuschke M, Metzen E, Iliakis G.
Chemical Inhibition of RPA by HAMNO Alters Cell Cycle Dynamics by Impeding DNA
Replication and G2-to-M Transition but Has Little Effect on the Radiation-
Induced DNA Damage Response. Int J Mol Sci. 2023 Oct 6;24(19):14941. doi:
10.3390/ijms241914941. PMID: 37834389; PMCID: PMC10573259.
3: Feng Y, Jiang Y, Liu J, Liu J, Shi M, Chen J, Zhang J, Tian Y, Yang X, Liu H.
Targeting RPA promotes autophagic flux and the antitumor response to radiation
in nasopharyngeal carcinoma. J Transl Med. 2023 Oct 19;21(1):738. doi:
10.1186/s12967-023-04574-w. PMID: 37858134; PMCID: PMC10585929.
4: Tian Yan H, Jang MS, Liu C, Fu Q, Wang B, Fu Y, Hee Lee J, Yu Yang H. Tumor
microenvironment activated mussel-inspired hollow mesoporous nanotheranostic for
enhanced synergistic photodynamic/chemodynamic therapy. J Colloid Interface Sci.
2024 Jul;665:188-203. doi: 10.1016/j.jcis.2024.03.133. Epub 2024 Mar 23. PMID:
38522159.
5: Glanzer JG, Liu S, Wang L, Mosel A, Peng A, Oakley GG. RPA inhibition
increases replication stress and suppresses tumor growth. Cancer Res. 2014 Sep
15;74(18):5165-72. doi: 10.1158/0008-5472.CAN-14-0306. Epub 2014 Jul 28. PMID:
25070753; PMCID: PMC4201622.
6: Sivasubramanian M, Chu CH, Cheng SH, Chen NT, Chen CT, Chuang YC, Yu H, Chen
YL, Liao LD, Lo LW. Multimodal Magnetic Resonance and Photoacoustic Imaging of
Tumor-Specific Enzyme-Responsive Hybrid Nanoparticles for Oxygen Modulation.
Front Bioeng Biotechnol. 2022 Jul 13;10:910902. doi: 10.3389/fbioe.2022.910902.
PMID: 35910012; PMCID: PMC9326367.
